Washington University Radiation Oncology at ESTRO 37

Washington University Radiation Oncology faculty and staff have recently returned from the 37^th Congress of the European Society for Therapeutic Radiation Oncology (ESTRO), held in late April in Barcelona, Spain.

Jeffrey Bradley, MD, a Washington University radiation oncologist at Siteman Cancer Center, participated in a lung cancer symposium about radiation dose escalation where he presented a 5-year review of the results from the RTOG 0617 trial, which tested the use of high- versus standard-dose radiotherapy for unresectable stage III non-small cell lung cancer, and the five subsequently published secondary analyses. Geoffrey Hugo, PhD, a Washington University medical physicist at Siteman Cancer Center, presented on the first in-human images acquired on a new linear accelerator prototype with CT imaging capabilities that has recently been installed at Washington University. Clinical resident Amar Srivastava’s abstract, “Early PD-1 blockade improves disease control for NSCLC brain metastases treated with radiosurgery” discussed a retrospective study that showed patients with non-small cell lung cancer brain metastases may have improved outcomes when immunotherapy with PD-1 inhibitors is used concurrently with stereotactic radiosurgery.

Erin Wittland, a radiation therapist from Barnes-Jewish Hospital working with Washington University Radiation Oncology at Siteman Cancer Center, presented at a pre-congress educational session that provided attendees with an overview of magnetic resonance imaging (MRI) and its implementation in a clinical radiotherapy practice. Her presentation discussed the department’s experience implementing a clinical workflow for MRI-guided radiotherapy, and the day-to-day clinical processes that have been developed over the last four years, including adaptive radiotherapy and real-time MR-gated treatments.

ESTRO 37 Gallery

• 

• 

• 

•